LT3230281T - 1,3-tiazol-2-ilu pakeisti benzamidai - Google Patents

1,3-tiazol-2-ilu pakeisti benzamidai

Info

Publication number: LT3230281T
Authority: LT; Lithuania
Prior art keywords: thiazol; substituted benzamides; benzamides; substituted
Prior art date: 2014-12-09

Application number

LTEP15804824.9T

Other languages

English (en)

Inventor

Adam James Davenport

Nico Braeuer

Oliver Martin Fischer

Andrea Rotgeri

Antje Rottmann

Ioana NEAGOE

Jens Nagel

Anne-Marie GODINHO-COELHO

Juergen Klar

Original Assignee

Bayer Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-09

Filing date

2015-12-07

Publication date

2021-07-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52015966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3230281(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-12-07 Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft

2021-07-12 Publication of LT3230281T publication Critical patent/LT3230281T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)

LTEP15804824.9T 2014-12-09 2015-12-07 1,3-tiazol-2-ilu pakeisti benzamidai LT3230281T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP14196954		2014-12-09
PCT/EP2015/078765 WO2016091776A1 (en)	2014-12-09	2015-12-07	1,3-thiazol-2-yl substituted benzamides

Publications (1)

Publication Number	Publication Date
LT3230281T true LT3230281T (lt)	2021-07-12

Family

ID=52015966

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP19181710.5T LT3587417T (lt)	2014-12-09	2015-12-07	1,3-tiazol-2-ilu pakeistieji benzamidai
LTEP15804824.9T LT3230281T (lt)	2014-12-09	2015-12-07	1,3-tiazol-2-ilu pakeisti benzamidai

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP19181710.5T LT3587417T (lt)	2014-12-09	2015-12-07	1,3-tiazol-2-ilu pakeistieji benzamidai

Country Status (42)

Country	Link
US (5)	US10174016B2 (lt)
EP (2)	EP3587417B9 (lt)
JP (2)	JP6544665B2 (lt)
KR (2)	KR102548799B1 (lt)
CN (2)	CN107207507B (lt)
AR (2)	AR102948A1 (lt)
AU (1)	AU2015359626B2 (lt)
BR (1)	BR112017012327B1 (lt)
CA (1)	CA2969952A1 (lt)
CL (1)	CL2017001488A1 (lt)
CO (1)	CO2017005742A2 (lt)
CR (2)	CR20170242A (lt)
CU (1)	CU24411B1 (lt)
CY (2)	CY1124486T1 (lt)
DK (2)	DK3230281T3 (lt)
DO (2)	DOP2017000137A (lt)
EA (2)	EA032312B1 (lt)
EC (1)	ECSP17036253A (lt)
ES (2)	ES2882952T3 (lt)
HR (2)	HRP20220371T1 (lt)
HU (2)	HUE055290T2 (lt)
IL (6)	IL252665B (lt)
JO (1)	JOP20150301B1 (lt)
LT (2)	LT3587417T (lt)
MA (2)	MA41135B1 (lt)
MX (2)	MX2020005909A (lt)
MY (1)	MY192690A (lt)
NI (1)	NI201700073A (lt)
NZ (1)	NZ761161A (lt)
PE (2)	PE20220253A1 (lt)
PH (1)	PH12017501079A1 (lt)
PL (2)	PL3230281T3 (lt)
PT (2)	PT3230281T (lt)
RS (2)	RS62227B1 (lt)
SG (2)	SG10202012274RA (lt)
SI (2)	SI3587417T1 (lt)
SV (1)	SV2017005461A (lt)
TN (1)	TN2017000244A1 (lt)
TW (2)	TWI716371B (lt)
UA (1)	UA120382C2 (lt)
UY (1)	UY36422A (lt)
WO (1)	WO2016091776A1 (lt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2969952A1 (en) *	2014-12-09	2016-06-16	Adam James Davenport	1,3-thiazol-2-yl substituted benzamides
TWI808055B (zh)	2016-05-11	2023-07-11	美商滬亞生物國際有限公司	Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh)	2016-05-11	2023-03-01	美商滬亞生物國際有限公司	Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN106588785A (zh) *	2016-12-02	2017-04-26	山东吉田香料股份有限公司	一种乙酰基吡嗪的制备方法
US10111883B1 (en) *	2017-09-18	2018-10-30	Bellus Health Cough Inc.	Selective P2X3 modulators
HU231206B1 (hu)	2017-12-15	2021-10-28	Richter Gedeon Nyrt.	Triazolobenzazepinek
CA3100096A1 (en)	2018-05-15	2019-11-21	Bayer Aktiengesellschaft	1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
US20210220358A1 (en) *	2018-05-15	2021-07-22	Bayer Aktiengesellschaft	1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
WO2020071530A1 (ja)	2018-10-05	2020-04-09	塩野義製薬株式会社	慢性咳嗽治療用医薬
EP3863640A4 (en) *	2018-10-10	2022-07-06	Bellus Health Cough Inc.	TREATMENT OF PRURITIS WITH P2X3 RECEPTOR ANTAGONISTS
CA3131312A1 (en)	2019-02-25	2020-09-03	Bellus Health Cough Inc.	Treatment with p2x3 modulators
BR112021019987A2 (pt) *	2019-04-05	2021-12-07	Syngenta Crop Protection Ag	Compostos de diazina-amida pesticidamente ativos
JP2022528181A (ja) *	2019-04-11	2022-06-08	シンジェンタクロッププロテクションアクチェンゲゼルシャフト	殺有害生物的に有効なジアジン－アミド化合物
WO2020239952A1 (en)	2019-05-31	2020-12-03	Chiesi Farmaceutici S.P.A.	Amino quinazoline derivatives as p2x3 inhibitors
MX2021014116A (es)	2019-05-31	2021-12-10	Chiesi Farm Spa	Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).
EP3757103A1 (en)	2019-06-27	2020-12-30	Bayer AG	Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases
CN113082023B (zh) *	2019-12-23	2024-03-01	武汉朗来科技发展有限公司	P2x3抑制剂和p2x4抑制剂的药物组合及其应用
WO2021238834A1 (zh) *	2020-05-25	2021-12-02	中国医药研究开发中心有限公司	芳甲酰胺类化合物及其制备方法和医药用途
WO2022063205A1 (zh) *	2020-09-24	2022-03-31	中国医药研究开发中心有限公司	芳基甲酰胺类化合物及其制备方法和医药用途
IL301667A (en) *	2020-09-30	2023-05-01	Humanwell Healthcare Group Co Ltd	Benzamide compound and use thereof
WO2022112493A1 (en)	2020-11-27	2022-06-02	Chiesi Farmaceutici S.P.A.	Phthalazine derivatives as p2x3 inhibitors
US20230416233A1 (en)	2020-11-27	2023-12-28	Chiesi Farmaceutici S.P.A.	(aza)quinoline 4-amines derivatives as p2x3 inhibitors
CA3196333A1 (en)	2020-11-27	2022-06-02	Claudio FIORELLI	Amino quinazoline derivatives as p2x3 inhibitors
WO2022253945A1 (en)	2021-06-04	2022-12-08	Bayer Aktiengesellschaft	Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide
WO2022253943A1 (en)	2021-06-04	2022-12-08	Bayer Aktiengesellschaft	Crystalline forms of 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}-benzamide
US12024285B1 (en)	2022-03-10	2024-07-02	Skypad Tech, Inc.	Modular mobility system including thrusters movably connected to a support structure
IL315933A (en) *	2022-03-29	2024-11-01	Humanwell Healthcare Group Co Ltd	P2x3 inhibitor compound, salt thereof, polymorph thereof and use thereof
CN118239941A (zh) *	2022-12-22	2024-06-25	人福医药集团股份公司	制备p2x3抑制剂的方法
WO2024240728A1 (en)	2023-05-22	2024-11-28	Chiesi Farmaceutici S.P.A.	Process and intermediates for the preparation of a p2x3 inhibitor
CN117777048B (zh) *	2023-09-25	2024-09-20	上海科利生物医药有限公司	一种手性2-羟甲基吗啉-4-羧酸叔丁酯的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006119504A2 (en)	2005-05-04	2006-11-09	Renovis, Inc.	Fused heterocyclic compounds, and compositions and uses thereof
CN103159692B (zh)	2006-06-29	2015-03-18	弗·哈夫曼-拉罗切有限公司	四唑取代的芳基酰胺类
US8501933B2 (en) *	2006-11-09	2013-08-06	Roche Palo Alto Llc	Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
EP2091927B1 (en)	2006-11-09	2011-07-20	F. Hoffmann-La Roche AG	Thiazole and oxazole-substituted arylamides
WO2008123963A1 (en)	2007-04-02	2008-10-16	Renovis, Inc.	Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
PT2139334E (pt)	2007-04-17	2013-10-02	Evotec Ag	Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
US20090099195A1 (en)	2007-05-08	2009-04-16	Astrazeneca Ab	Therapeutic Compounds 570
US20090317360A1 (en) *	2007-06-12	2009-12-24	Genelabs Technologies, Inc.	Anti-viral inhibitors and methods of use
WO2009058298A1 (en)	2007-10-31	2009-05-07	Merck & Co., Inc.	P2x3, receptor antagonists for treatment of pain
AU2008319309B2 (en)	2007-10-31	2012-09-06	Merck Sharp & Dohme Llc	P2X3 receptor antagonists for treatment of pain
JP5301561B2 (ja)	2007-12-17	2013-09-25	エフ．ホフマン−ラロシュアーゲー	新規なピラゾール置換アリールアミド
WO2009077366A1 (en)	2007-12-17	2009-06-25	F. Hoffmann-La Roche Ag	Triazole-substituted arylamide derivatives and their use as p2x3 and /or p2x2/3 purinergic receptor antagonists
CN101903355B (zh)	2007-12-17	2014-05-14	霍夫曼-拉罗奇有限公司	咪唑取代的芳基酰胺
ES2517602T3 (es)	2007-12-17	2014-11-03	F. Hoffmann-La Roche Ag	Derivados arilamida sustituidos con tetrazol y su utilización como antagonistas de receptores purinérgicos P2X3 y/o P2X2/3
CN104058999A (zh)	2008-02-29	2014-09-24	伊沃泰克股份公司	酰胺化合物、组合物及其应用
JP5608655B2 (ja)	2008-09-18	2014-10-15	エヴォテックアーゲー	Ｐ２ｘ３受容体活性のモジュレーター
MX2011004570A (es) *	2008-10-31	2011-06-17	Merck Sharp & Dohme	Antagonistas del receptor p2x3 para el tratamiento del dolor.
AU2009328347B2 (en)	2008-12-16	2016-06-09	F. Hoffmann-La Roche Ag	Thiadiazole-substituted arylamides
SG176640A1 (en)	2009-06-22	2012-01-30	Hoffmann La Roche	Novel oxazolone and pyrrolidinone-substituted arylamides
SG177308A1 (en)	2009-06-22	2012-02-28	Hoffmann La Roche	Novel biphenyl and phenyl-pyridine amides
BR112012017441B1 (pt)	2010-01-13	2019-11-19	Tempero Pharmaceuticals Inc	compostos e métodos
WO2013009810A1 (en)	2011-07-13	2013-01-17	Tempero Pharmaceuticals, Inc.	Methods of treatment
US9562041B2 (en) *	2012-05-16	2017-02-07	Glaxosmithkline Llc	Enhancer of zeste homolog 2 inhibitors
JP6254169B2 (ja)	2012-09-28	2017-12-27	ファイザー・インク	ベンズアミドおよびヘテロベンズアミド化合物
AU2014211962B2 (en)	2013-01-31	2017-11-16	Bellus Health Cough Inc.	Imidazopyridine compounds and uses thereof
CA2969952A1 (en)	2014-12-09	2016-06-16	Adam James Davenport	1,3-thiazol-2-yl substituted benzamides
US10183937B2 (en) *	2014-12-09	2019-01-22	Bayer Aktiengesellschaft	1,3-thiazol-2-yl substituted benzamides
CA3100096A1 (en)	2018-05-15	2019-11-21	Bayer Aktiengesellschaft	1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
US20210220358A1 (en)	2018-05-15	2021-07-22	Bayer Aktiengesellschaft	1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EP3757103A1 (en)	2019-06-27	2020-12-30	Bayer AG	Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases

2015
- 2015-12-07 CA CA2969952A patent/CA2969952A1/en active Pending
- 2015-12-07 UY UY0001036422A patent/UY36422A/es active IP Right Grant
- 2015-12-07 SI SI201531781T patent/SI3587417T1/sl unknown
- 2015-12-07 CN CN201580075714.1A patent/CN107207507B/zh not_active Expired - Fee Related
- 2015-12-07 CR CR20170242A patent/CR20170242A/es unknown
- 2015-12-07 PE PE2021001723A patent/PE20220253A1/es unknown
- 2015-12-07 HU HUE15804824A patent/HUE055290T2/hu unknown
- 2015-12-07 PT PT158048249T patent/PT3230281T/pt unknown
- 2015-12-07 JP JP2017530625A patent/JP6544665B2/ja active Active
- 2015-12-07 PL PL15804824T patent/PL3230281T3/pl unknown
- 2015-12-07 SG SG10202012274RA patent/SG10202012274RA/en unknown
- 2015-12-07 EA EA201791261A patent/EA032312B1/ru not_active IP Right Cessation
- 2015-12-07 ES ES15804824T patent/ES2882952T3/es active Active
- 2015-12-07 EP EP19181710.5A patent/EP3587417B9/en active Active
- 2015-12-07 US US15/534,855 patent/US10174016B2/en active Active
- 2015-12-07 JO JOP/2015/0301A patent/JOP20150301B1/ar active
- 2015-12-07 CN CN201910653985.0A patent/CN110256418B/zh not_active Expired - Fee Related
- 2015-12-07 MA MA41135A patent/MA41135B1/fr unknown
- 2015-12-07 PT PT191817105T patent/PT3587417T/pt unknown
- 2015-12-07 HU HUE19181710A patent/HUE058009T2/hu unknown
- 2015-12-07 RS RS20211014A patent/RS62227B1/sr unknown
- 2015-12-07 TN TN2017000244A patent/TN2017000244A1/en unknown
- 2015-12-07 PE PE2017000984A patent/PE20180227A1/es unknown
- 2015-12-07 NZ NZ761161A patent/NZ761161A/en unknown
- 2015-12-07 BR BR112017012327-4A patent/BR112017012327B1/pt not_active IP Right Cessation
- 2015-12-07 RS RS20220250A patent/RS63014B1/sr unknown
- 2015-12-07 AU AU2015359626A patent/AU2015359626B2/en not_active Ceased
- 2015-12-07 KR KR1020177018575A patent/KR102548799B1/ko active IP Right Grant
- 2015-12-07 WO PCT/EP2015/078765 patent/WO2016091776A1/en active Application Filing
- 2015-12-07 MY MYPI2017702127A patent/MY192690A/en unknown
- 2015-12-07 UA UAA201707107A patent/UA120382C2/uk unknown
- 2015-12-07 EA EA201891120A patent/EA034273B1/ru not_active IP Right Cessation
- 2015-12-07 LT LTEP19181710.5T patent/LT3587417T/lt unknown
- 2015-12-07 MA MA50674A patent/MA50674B1/fr unknown
- 2015-12-07 CR CR20210108A patent/CR20210108A/es unknown
- 2015-12-07 MX MX2020005909A patent/MX2020005909A/es unknown
- 2015-12-07 SI SI201531643T patent/SI3230281T1/sl unknown
- 2015-12-07 EP EP15804824.9A patent/EP3230281B1/en active Active
- 2015-12-07 MX MX2017007658A patent/MX2017007658A/es active IP Right Grant
- 2015-12-07 LT LTEP15804824.9T patent/LT3230281T/lt unknown
- 2015-12-07 DK DK15804824.9T patent/DK3230281T3/da active
- 2015-12-07 SG SG11201704717VA patent/SG11201704717VA/en unknown
- 2015-12-07 PL PL19181710T patent/PL3587417T3/pl unknown
- 2015-12-07 DK DK19181710.5T patent/DK3587417T3/da active
- 2015-12-07 KR KR1020237021217A patent/KR20230098368A/ko active Application Filing
- 2015-12-07 HR HRP20220371TT patent/HRP20220371T1/hr unknown
- 2015-12-07 ES ES19181710T patent/ES2908822T3/es active Active
- 2015-12-07 CU CU2017000077A patent/CU24411B1/es unknown
- 2015-12-08 TW TW104141168A patent/TWI716371B/zh not_active IP Right Cessation
- 2015-12-08 TW TW110100512A patent/TWI780562B/zh not_active IP Right Cessation
- 2015-12-09 AR ARP150104007A patent/AR102948A1/es unknown
2017
- 2017-06-05 IL IL25266517A patent/IL252665B/en active IP Right Grant
- 2017-06-08 PH PH12017501079A patent/PH12017501079A1/en unknown
- 2017-06-09 CL CL2017001488A patent/CL2017001488A1/es unknown
- 2017-06-09 CO CONC2017/0005742A patent/CO2017005742A2/es unknown
- 2017-06-09 NI NI201700073A patent/NI201700073A/es unknown
- 2017-06-09 EC ECIEPI201736253A patent/ECSP17036253A/es unknown
- 2017-06-09 SV SV2017005461A patent/SV2017005461A/es unknown
- 2017-06-09 DO DO2017000137A patent/DOP2017000137A/es unknown
- 2017-11-21 US US15/820,429 patent/US10202369B2/en active Active
2018
- 2018-08-08 DO DO2018000182A patent/DOP2018000182A/es unknown
- 2018-11-13 JP JP2018212898A patent/JP6647371B2/ja not_active Expired - Fee Related
- 2018-11-15 US US16/192,314 patent/US10472354B2/en active Active
2019
- 2019-09-19 IL IL269468A patent/IL269468B/en active IP Right Grant
- 2019-09-19 IL IL269467A patent/IL269467B/en active IP Right Grant
- 2019-09-25 IL IL269661A patent/IL269661B/en active IP Right Grant
- 2019-10-01 US US16/589,838 patent/US11142523B2/en active Active
2020
- 2020-06-07 IL IL275183A patent/IL275183B/en active IP Right Grant
- 2020-08-13 AR ARP200102296A patent/AR119761A2/es unknown
2021
- 2021-06-14 IL IL283979A patent/IL283979B/en unknown
- 2021-06-24 HR HRP20211002TT patent/HRP20211002T1/hr unknown
- 2021-08-20 CY CY20211100750T patent/CY1124486T1/el unknown
- 2021-09-09 US US17/470,459 patent/US20230053411A1/en not_active Abandoned
2022
- 2022-03-15 CY CY20221100217T patent/CY1125083T1/el unknown

Also Published As

Publication number	Publication date
US20200131169A1 (en)	2020-04-30
IL269661B (en)	2020-07-30
MX2020005909A (es)	2021-10-28
EP3587417A1 (en)	2020-01-01
SI3587417T1 (sl)	2022-04-29
TWI780562B (zh)	2022-10-11
CY1125083T1 (el)	2023-06-09
JP2019059742A (ja)	2019-04-18
EA201891120A1 (ru)	2018-10-31
IL269467A (en)	2019-11-28
WO2016091776A1 (en)	2016-06-16
DOP2018000182A (es)	2018-09-15
PT3230281T (pt)	2021-08-19
HUE055290T2 (hu)	2021-11-29
MA50674B1 (fr)	2022-11-30
DK3230281T3 (da)	2021-08-16
CN110256418B (zh)	2023-01-20
RS63014B1 (sr)	2022-04-29
IL252665B (en)	2019-10-31
US20230053411A1 (en)	2023-02-23
US10472354B2 (en)	2019-11-12
IL269468A (en)	2019-11-28
CN107207507B (zh)	2020-11-06
IL269661A (en)	2019-11-28
EP3587417B9 (en)	2022-03-30
CR20170242A (es)	2018-02-02
PH12017501079A1 (en)	2017-10-18
IL269467B (en)	2020-08-31
CR20210108A (es)	2021-04-27
EP3230281A1 (en)	2017-10-18
PE20220253A1 (es)	2022-02-16
CN110256418A (zh)	2019-09-20
JP6647371B2 (ja)	2020-02-14
PT3587417T (pt)	2022-03-16
US20180118731A1 (en)	2018-05-03
DK3587417T3 (da)	2022-03-28
RS62227B1 (sr)	2021-09-30
AR119761A2 (es)	2022-01-12
ECSP17036253A (es)	2017-06-30
NZ733108A (en)	2022-03-25
SV2017005461A (es)	2018-04-30
PL3587417T3 (pl)	2022-06-13
IL252665A0 (en)	2017-08-31
UA120382C2 (uk)	2019-11-25
AR102948A1 (es)	2017-04-05
CU24411B1 (es)	2019-05-03
EP3230281B1 (en)	2021-05-26
MX2017007658A (es)	2018-08-01
AU2015359626A1 (en)	2017-06-29
CO2017005742A2 (es)	2017-09-20
NI201700073A (es)	2017-10-24
DOP2017000137A (es)	2017-07-31
IL275183B (en)	2021-06-30
ES2908822T3 (es)	2022-05-04
EA201791261A1 (ru)	2017-12-29
HUE058009T2 (hu)	2022-06-28
KR20170093203A (ko)	2017-08-14
PL3230281T3 (pl)	2021-12-13
CA2969952A1 (en)	2016-06-16
JP6544665B2 (ja)	2019-07-17
EP3587417B1 (en)	2022-01-05
US20190185466A1 (en)	2019-06-20
TW202130637A (zh)	2021-08-16
TW201629053A (zh)	2016-08-16
BR112017012327A2 (pt)	2018-02-27
BR112017012327A8 (pt)	2021-02-23
BR112017012327B1 (pt)	2023-04-11
PE20180227A1 (es)	2018-01-31
KR102548799B1 (ko)	2023-06-27
EA034273B1 (ru)	2020-01-23
CY1124486T1 (el)	2022-07-22
SI3230281T1 (sl)	2021-08-31
CL2017001488A1 (es)	2018-02-23
US20180093980A1 (en)	2018-04-05
EA032312B1 (ru)	2019-05-31
IL283979A (en)	2021-07-29
AU2015359626B2 (en)	2020-07-23
TN2017000244A1 (en)	2018-10-19
HRP20220371T1 (hr)	2022-05-13
UY36422A (es)	2016-06-30
US10174016B2 (en)	2019-01-08
JOP20150301B1 (ar)	2023-09-17
IL269468B (en)	2020-06-30
SG11201704717VA (en)	2017-08-30
IL283979B (en)	2022-04-01
KR20230098368A (ko)	2023-07-03
IL275183A (en)	2020-07-30
CU20170077A7 (es)	2017-11-07
MA41135B1 (fr)	2021-10-29
MY192690A (en)	2022-09-01
SG10202012274RA (en)	2021-01-28
HRP20211002T1 (hr)	2021-09-17
ES2882952T3 (es)	2021-12-03
US11142523B2 (en)	2021-10-12
LT3587417T (lt)	2022-02-10
TWI716371B (zh)	2021-01-21
NZ761161A (en)	2024-04-26
US10202369B2 (en)	2019-02-12
JP2017537122A (ja)	2017-12-14
MA50674A (fr)	2021-03-31
CN107207507A (zh)	2017-09-26

Publication	Publication Date	Title
IL283979B (en)	2022-04-01	3,1-thiazol-2-yl converted benzamides
GB201413021D0 (en)	2014-09-03	Beyond 2
GB201418612D0 (en)	2014-12-03	Umajin 1
GB201418846D0 (en)	2014-12-03	MicroSub 1
GB201416254D0 (en)	2014-10-29	LiftEye 2014
GB201414175D0 (en)	2014-09-24	Pris-map 1
GB201413386D0 (en)	2014-09-10	Taggstar 2
GB201413313D0 (en)	2014-09-10	Kapiche 1
GB201413310D0 (en)	2014-09-10	Taggstar 2
GB201412713D0 (en)	2014-09-03	Soundwall 2
GB201412900D0 (en)	2014-09-03	The brolly head
GB201408307D0 (en)	2014-06-25	Pakaging 22
GB201408330D0 (en)	2014-06-25	Pckaging 32
GB201406497D0 (en)	2014-05-28	Skytag 2
GB201401037D0 (en)	2014-03-05	54545
GB201418606D0 (en)	2014-12-03	Lifteye october 2014
GB201416686D0 (en)	2014-11-05	Cine 8
GB201406945D0 (en)	2014-06-04	The micro-matchbox effect